Phase i study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528

Shirish M. Gadgeel, Danika L. Lew, Timothy W. Synold, Patricia Lorusso, Vincent Chung, Scott D Christensen, David C. Smith, Laura Kingsbury, Antje Hoering, Razelle Kurzrock

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'Phase i study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences